| GTO ID | GTC0516 |
| Trial ID |
NCT04245839
|
| Disease |
Non-Hodgkin's Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) |
| Year | 2020 |
| Country | United States |
| Company sponsor | Celgene |
| Other ID(s) | JCAR017-FOL-001|U1111-1244-9768|2019-004081-18 |